Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple SclerosisEline M. E. Coerver, Eva Strijbis, Jop Mostert et al.|JAMA Neurology|2024Cited by 29
Association of volumetric MRI measures and disability in MS patients of the same age: Descriptions from a birth year cohortLodewijk R. J. de Ruiter, Bernard M.J. Uitdehaag, Menno M. Schoonheim et al.|Multiple Sclerosis and Related Disorders|2023Cited by 11
Long-term neuroprotective effects of natalizumab and fingolimod in multiple sclerosis: Evidence from real-world clinical dataSamantha Noteboom, Martijn D. Steenwijk, Bas Jasperse et al.|Multiple Sclerosis and Related Disorders|2024Cited by 5
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)Wing Hee Fung, Eva Strijbis, Jop Mostert et al.|Journal of Neurology|2025Cited by 4